Penumbra Inc
PEN261.290USD
+4.790+1.87%
Market hours （ET）Quotes delayed by 15 min
10.11BMarket Cap
721.36P/E TTM
More Details of Penumbra Inc Company
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Info
Ticker SymbolPEN
Company namePenumbra Inc
IPO dateSep 18, 2015
Founded at2004
CEOMr. Adam Elsesser, J.D.
Number of employees4500
Security typeOrdinary Share
Fiscal year-endSep 18
AddressOne Penumbra Place
CityALAMEDA
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code94502
Phone15109952486
Websitehttps://www.penumbrainc.com/
Ticker SymbolPEN
IPO dateSep 18, 2015
Founded at2004
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Adam Elsesser, J.D.
Mr. Adam Elsesser, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
947.94K
+1.29%
Dr. Arani Bose, M.D.
Dr. Arani Bose, M.D.
Director
Director
302.26K
-3.82%
Ms. Johanna Roberts
Ms. Johanna Roberts
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
52.14K
-1.14%
Mr. Lambert Shiu
Mr. Lambert Shiu
Chief Accounting Officer
Chief Accounting Officer
25.61K
-4.98%
Ms. Janet Leeds
Ms. Janet Leeds
Independent Director
Independent Director
5.49K
-1.06%
Ms. Bridget O'Rourke
Ms. Bridget O'Rourke
Independent Director
Independent Director
4.87K
-2.01%
Ms. Surbhi Sarna
Ms. Surbhi Sarna
Independent Director
Independent Director
3.15K
-1.84%
Ms. Maggie S. Yuen
Ms. Maggie S. Yuen
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Thomas C. (Tom) Wilder, III
Mr. Thomas C. (Tom) Wilder, III
Presiding Independent Director
Presiding Independent Director
--
--
Mr. Harpreet S. Grewal
Mr. Harpreet S. Grewal
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Adam Elsesser, J.D.
Mr. Adam Elsesser, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
947.94K
+1.29%
Dr. Arani Bose, M.D.
Dr. Arani Bose, M.D.
Director
Director
302.26K
-3.82%
Ms. Johanna Roberts
Ms. Johanna Roberts
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
52.14K
-1.14%
Mr. Lambert Shiu
Mr. Lambert Shiu
Chief Accounting Officer
Chief Accounting Officer
25.61K
-4.98%
Ms. Janet Leeds
Ms. Janet Leeds
Independent Director
Independent Director
5.49K
-1.06%
Ms. Bridget O'Rourke
Ms. Bridget O'Rourke
Independent Director
Independent Director
4.87K
-2.01%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Thrombectomy
815.48M
68.26%
Embolization and Access
379.14M
31.74%
By RegionUSD
Name
Revenue
Proportion
United States
902.07M
75.51%
International
292.55M
24.49%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Thrombectomy
815.48M
68.26%
Embolization and Access
379.14M
31.74%
Shareholding Stats
Updated: Mon, May 19
Updated: Mon, May 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.77%
The Vanguard Group, Inc.
9.47%
BlackRock Institutional Trust Company, N.A.
9.11%
State Street Global Advisors (US)
3.09%
T. Rowe Price Associates, Inc.
3.04%
Other
62.52%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.77%
The Vanguard Group, Inc.
9.47%
BlackRock Institutional Trust Company, N.A.
9.11%
State Street Global Advisors (US)
3.09%
T. Rowe Price Associates, Inc.
3.04%
Other
62.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.29%
Investment Advisor/Hedge Fund
30.30%
Hedge Fund
6.74%
Individual Investor
3.54%
Pension Fund
1.71%
Research Firm
1.40%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.53%
Venture Capital
0.17%
Other
4.70%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
851
36.94M
95.40%
-4.28M
2024Q4
834
37.02M
96.10%
-3.78M
2024Q3
813
37.33M
96.12%
-2.93M
2024Q2
796
37.57M
96.93%
+395.13K
2024Q1
777
35.67M
92.18%
-2.09M
2023Q4
759
36.33M
94.13%
-67.98K
2023Q3
737
35.15M
91.46%
-2.09M
2023Q2
719
36.20M
94.64%
-1.94M
2023Q1
681
37.31M
97.62%
-964.82K
2022Q4
661
36.89M
97.22%
+885.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
4.85M
12.6%
-93.71K
-1.89%
Dec 31, 2024
The Vanguard Group, Inc.
3.64M
9.46%
-25.90K
-0.71%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.50M
9.08%
+25.93K
+0.75%
Dec 31, 2024
State Street Global Advisors (US)
1.20M
3.12%
-33.45K
-2.71%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.23M
3.21%
-702.67K
-36.27%
Dec 31, 2024
Elsesser (Adam)
985.33K
2.56%
+22.75K
+2.36%
Mar 19, 2025
Fidelity Institutional Asset Management
965.15K
2.51%
+16.18K
+1.71%
Dec 31, 2024
Champlain Investment Partners, LLC
1.50M
3.88%
-52.02K
-3.36%
Dec 31, 2024
RTW Investments L.P.
862.45K
2.24%
+66.70K
+8.38%
Dec 31, 2024
Citadel Advisors LLC
734.29K
1.91%
+322.26K
+78.22%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Motley Fool Small-Cap Growth ETF
3.68%
First Trust Health Care Alphadex Fund
2.24%
Congress SMid Growth ETF
2.21%
First Trust Indxx Medical Devices ETF
1.84%
ROBO Global Healthcare Technology & Innovation ETF
1.82%
SPDR S&P Health Care Equipment ETF
1.79%
Tema Neuroscience and Mental Health ETF
1.78%
Putnam Sustainable Future ETF
1.53%
iShares U.S. Medical Devices ETF
1.24%
ProShares Metaverse ETF
1.16%
View more
Motley Fool Small-Cap Growth ETF
Proportion3.68%
First Trust Health Care Alphadex Fund
Proportion2.24%
Congress SMid Growth ETF
Proportion2.21%
First Trust Indxx Medical Devices ETF
Proportion1.84%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.82%
SPDR S&P Health Care Equipment ETF
Proportion1.79%
Tema Neuroscience and Mental Health ETF
Proportion1.78%
Putnam Sustainable Future ETF
Proportion1.53%
iShares U.S. Medical Devices ETF
Proportion1.24%
ProShares Metaverse ETF
Proportion1.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
